A new study published in the journal of Pediatric Dermatology revealed that treatment with dupilumab achieved effective ...

Topical pumecitinib 3% gel shows strong efficacy and good tolerability in mild-to-moderate atopic dermatitis. Explore the ...

Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.

INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

Arcutis Biotherapeutics recently reported positive topline results from its INTEGUMENT-INFANT Phase 2 trial, showing that ZORYVE cream 0.05% improved disease severity and was well tolerated in 101 ...

Oncodermatology is evolving with nonsurgical approaches and immune checkpoint inhibitors, improving outcomes in aggressive ...

Russian drugmaker Binnopharm Group together with China’s Mabwell announced plans to localize the production of a monoclonal ...

Arcutis Biotherapeutics develops topical therapies for chronic skin conditions, with a portfolio targeting psoriasis and atopic dermatitis.

With shares down more than 40% since November, the risk-reward for Nektar Therapeutics has shifted ahead of pivotal clinical ...

GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced that it will present a poster on its lead candidate, ...

Sanofi (ENXTPA:SAN) reported that its investigational therapy venglustat met all primary endpoints in a Phase 3 trial for type 3 Gaucher disease, a rare neurological condition with no approved ...

A Phase III readout in September 2024 for rocatinlimab, on which Amgen and Kyowa Kirin were collaborating in atopic dermatitis, appeared underwhelming to analysts, with Jefferies noting that the data ...